Details for Patent: 6,229,002
✉ Email this page to a colleague
Title: | Platelet derived growth factor (PDGF) nucleic acid ligand complexes |
Abstract: | This invention discloses a method for preparing a complex comprised of a PDGF Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound by identifying a PDGF Nucleic Acid Ligand by SELEX methodology and associating the PDGF Nucleic Acid Ligand with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further discloses Complexes comprising one or more PDGF Nucleic Acid Ligands in association with a Non-Immunogenic, High Molecular Weight Compound or Lipophilic Compound. The invention further includes a Lipid construct comprising a PDGF Nucleic Acid Ligand or Complex and methods for making the same. |
Inventor(s): | Janjic; Nebojsa (Boulder, CO), Gold; Larry (Boulder, CO) |
Assignee: | NeXstar Pharmaceuticlas, Inc. (Boulder, CO) |
Filing Date: | Dec 16, 1997 |
Application Number: | 08/991,743 |
Claims: | 1. A Complex comprised of a platelet-derived growth factor (PDGF) Nucleic Acid Ligand and a Non-Immunogenic, High Molecular Weight Compound. 2. The Complex of claim 1 further comprising a Linker between said Ligand and said Non-Immunogenic, High Molecular Weight Compound. 3. The Complex of claim 1 wherein said Ligand comprises a Linker. 4. The Complex of claim 1 wherein said Non-Immunogenic, High Molecular Weight Compound is a Polyalkylene Glycol. 5. The Complex of claim 4 wherein said Polyalkylene Glycol is polyethylene glycol. 6. The Complex of claim 5 wherein said polyethylene glycol has a molecular weight of about 10-80 K. 7. The Complex of claim 6 wherein said polyethylene glycol has a molecular weight of about 20-45 K. 8. A Lipid Construct comprising the Complex of claim 1. 9. The Complex of claim 1 wherein said PDGF Nucleic Acid Ligand is identified from a Candidate Mixture of Nucleic Acids according to the method comprising: a) contacting the Candidate Mixture with PDGF, wherein the Nucleic Acids having an increased affinity to PDGF relative to the Candidate Mixture may be partitioned from the remainder of the Candidate Mixture; b) partitioning the increased affinity Nucleic Acids from the remainder of the Candidate Mixture; and c) amplifying the increased affinity Nucleic Acids to yield a mixture of Nucleic Acids enriched for Nucleic Acids having an increased affinity for PDGF; whereby a Nucleic Acid Ligand of PDGF is identified. 10. The Complex of claim 9 wherein the method further comprises repeating steps b) and c). 11. The complex of claim 7 wherein said Complex is ##STR36## in which said PEG spacer is ##STR37## and said nucleic acid ligand comprises SEQ ID NO:146. |